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August 2012 marked the 40th anniversary of Günter Wulff’s 
inaugural molecular imprinting paper that demonstrated 
imprinting within an organic polymer [1]. Some twenty years 
later, in February 1993, the group of Klaus Mosbach published 
their milestone study in Nature where, for the first time, non-
covalent molecular imprints were employed in a competitive 
binding assay for the detection/quantitation of theophylline and 
diazepam in human serum [2]. Cited almost 1,200 times, this 
paper helped popularise the technique of imprinting as a means 
of generating synthetic recognition materials and, decades after 
the first report of molecular imprinting, spawned the phrase 
‘antibody mimics’; a term now synonymous with the technology. 
The authors hypothesised that the technology would, one day, 
provide a ‘useful, general alternative to antibodies’.
The Vlatakis et al. paper was the first demonstration of 
MIPs being successfully used as alternatives for antibodies 
in competitive binding assays. The results reported were, and 
still are, impressive with molecular imprinted polymer (MIP) 
dissociation constants (Kd) in the nanomolar range and when 
challenged with a range of structurally related competitive 
ligands, cross-reactivity profiles correlating with those observed 
with antibodies (Table 1). However, the key difference between 
the MIP assay and a typical immunoassay was the environment 
in which the assays were performed. Antibodies have the ability 
to efficiently bind their antigen with high affinity directly from 
complex biological milieu, whereas the MIP system required 
extraction of drug into organic solvents, namely acetonitrile/
acetic acid and toluene/heptane mixtures, in order to optimise 
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Abstract
In February 1993, the group of Klaus Mosbach published their milestone 
study in Nature where, for the first time, non-covalent molecular imprints 
were employed in a competitive binding assay. In this seminal piece 
of work, and also for the first time, they refer to molecularly imprinted 
polymers as being ‘antibody mimics’ and hypothesised that these synthetic 
materials could one day provide ‘a useful, general alternative to antibodies’. 
This perspective article examines how far we have come in the 20 years 
since this publication in terms of realising this hypothesis and poses the 
question of whether we actually need molecularly imprinted polymers to be 
a general alternative to antibodies.
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performance. As a consequence, the MIP assay took longer and 
was more resource intensive than conventional ELISA – type 
approaches. Nonetheless, should the authors have sought to 
apply their antibody assay system in the organic phase, under 
the same experimental conditions in which the MIP assay was 
shown to be so effective, they would have been met with failure; 
a point often under-stated when MIP researchers are striving to 
mimic biological assays. The polymers described in the paper 
Cross-reactivity (%)
MIP Antibody
Theophylline and related substances
theophylline 100 100
3-methylxanthine 7 2
caffeine < 1 < 1
theobromine < 1 < 1
uric acid < 1 < 1
Diazepam and related substances
diazepam 100 100
alprazolam 40 44
desmethyldiazepam 27 32
clonazepam 9 5
lorazepam 4 1
Table 1.  Cross reactivity data comparing the performance of the MIP 
employed in the competitive binding studies published by Vlatakis 
et al. to that of an antibody [2].
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MIPs seem to have a clear advantage: their preparation is 
much simpler, quicker and cheaper compared to their natural 
counterparts, their application range is much wider in terms 
of solvent, pH and temperature conditions, while their stability 
over time and reusability are exceptional compared to any other 
affinity sorbent.
Researchers aiming to capitalise on the benefits listed 
in Table 2 have adapted and employed molecular imprints 
to a variety of applications spanning most, if not all, ex vivo 
processes where selective recognition/binding is required and 
where an antibody would be typically used. Thus, at the time 
of writing, the database of imprinting literature reports more 
than 8,400 publications [4] associated with a highly diverse 
range of ‘antigens’ or templates as they are commonly termed 
in molecular imprinting. This large library of molecules can be 
broadly divided in two categories based on molecular size. There 
are the small molecules with molecular weights (M.W.) up to 
1,000 Da, which among others include environmental pollutants 
[5], food additives or contaminants [6], pharmaceuticals [7] and 
drugs of abuse [8,9], and the larger molecules with M.W. up to or 
exceeding 100,000 Da, typically small to medium size peptides 
and proteins [10].
possessed a range of binding sites of varying affinities, making 
them polyclonal as opposed to monoclonal mimics but of 
course, being simple synthetic polymers, they would have been 
considerably more stable and more readily prepared than their 
biological counterparts.   
In the 20 years following this milestone publication we have 
seen a huge increase in the number of researchers involved in 
the field of molecular imprinting with an associated dramatic 
increase in the number of publications (Figure 1) [3]. However, in 
spite of the significant interest the technology has attracted, have 
we come any closer to Vlatakis et al.’s hypothesis that one day 
MIPs would become ‘useful, general alternative to antibodies’?
Table 2 summarises some of the qualitative and quantitative 
features of antibodies and MIPs, upon which comparisons 
between the two receptor types are usually based. Apart from 
their well-documented high selectivity, antibodies also have the 
edge in terms of affinity, with Kd values often in the picomolar 
range as compared to low micro - nanomolar for MIPs. This is 
a crucial point in that assay sensitivity is directly linked to the 
affinity of the receptor and therefore detection limits for a MIP 
assay will, at best, be nanomolar but more commonly micro- or 
even millimolar. However, in all other aspects of this comparison 
Figure 1.  Cumulative number of MIP articles published since 1932.  Data generated from www.mipdatabase.com (accessed on 05/02/2013) [4]
Antibodies MIPs
Affinity 10-7 – 10-11 M 10-3 – 10-10 M
Application Physiological conditions Organic or aqueous media
Capacity ~ 6 μmol.g-1 ~ 0.1 – 10 μmol.g-1
Cost £100’s for μg quantities £10’s for g quantities
Production Animal host, months 2 – 3 days
Reusability Not usually 100’s of times
Stability Narrow temperature and pH range Wide temperature and pH range
Storage time Limited Stable over period of years
Table 2.  Typical characteristics of antibodies and MIPs.
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Conventional bulk imprinting approaches and the synthesis of 
imprinted soft gels both suffer from inefficient removal of the 
template and poor mass transfer upon re-incubation with their 
target species [22]. As a result, efforts have primarily focused on 
the use of surface imprinting approaches to allow for unhindered 
access to recognition sites. Early studies employed metal ion 
co-ordinated imprinting as an approach for the recognition of 
proteins [23-25] and although the systems were efficient at 
rebinding their templates, the application of this imprinting 
technique is limited to proteins that express histidine residues 
on their surface. Hierarchical imprinting has also been used 
to generate recognition elements for peptides. The use of a 
sacrificial solid support such as silica, allows for the generation 
of surface confined binding sites that are more homogenous 
than those in conventional imprinted polymer systems [26,27]. 
This homogeneity arises from the fact that the template is 
immobilised during the imprinting process, eliminating the 
probability for random incorporation in the polymer matrix and 
limiting the number of different possible complexes, however the 
main drawback of such an approach is the necessity for harsh 
conditions to bring about removal of the solid support.
In 2000, Rachkov and Minoura demonstrated what is 
termed ‘the epitope approach’ to molecular imprinting for the 
first time [28,29]. They imprinted a tetra-peptide sequence from 
oxytocin, a natural peptidic hormone, in acetonitrile containing 
3% water. Importantly, it was found that recognition of the full 
peptide was possible using the epitopic tetra-peptide MIP, 
thus demonstrating the feasibility of using epitope sequences 
as templates when targeting recognition of macromolecules. 
However, despite delivering good chromatographic performance 
with high-acetonitrile mobile phases, when the water content 
was increased a significant reduction in retention time was 
observed due to the loss of hydrogen bonding interactions 
between the template and the polymer. Ken Shea’s group 
further progressed this technique, achieving recognition of larger 
protein structures (cytochrome C, bovine serum albumin and 
alcohol dehydrogenase) through the imprinting of a nonapeptide 
sequence isolated from the C-terminus of the proteins [30]. 
Recently, the same group demonstrated the use of molecularly 
imprinted polymers in an in vivo system for the first time [31]. 
The polymers, imprinted with the 26 amino acid peptide mellitin 
(from bee venom), demonstrated affinities in the picomolar range 
and comparable to those achieved with antibodies [32,33]. To 
achieve such affinities for a biological macromolecule through 
polymerisation in wholly aqueous conditions is undisputedly a 
major advancement for the field of molecular imprinting.
Such examples offer clear evidence that molecular imprinting 
has evolved significantly over the past two decades; a result of 
the continuous and dedicated efforts of the researchers working 
in the field. So, are we any closer to preparing molecularly 
imprinted ‘synthetic antibodies’? From a literal perspective this 
is a difficult question to answer. While we can safely say that 
we have witnessed the evolution of a new class of materials 
with unique properties that in specific cases match or exceed 
those of antibodies, a direct and general comparison between 
Akin to the publication by Vlatakis et al., the bulk of MIP 
literature refers to polymers molecularly imprinted with substances 
that fall into the first category of small molecules. These are 
typically soluble in aprotic, low-polarity organic solvents (such 
as toluene, chloroform or acetonitrile), have a definite, often 
conformationally restricted, shape and confined functionality that 
can be matched to one or more commercially available or custom 
made functional monomers and in most cases are light and/or 
heat stable. These properties make them ideal candidates for a 
textbook imprinting protocol whereby functional monomer(s), 
cross-linker(s) and initiator are mixed with the template in the 
solvent of choice and the resulting homogenous solution is 
thermally or photo-chemically polymerised to form a monolithic 
imprinted polymer [11]. Subsequent grinding, sieving and removal 
of the template, by solvent extraction, produces a ‘plastic 
antibody’ [12] in relatively good yields, short preparation time and 
at low cost. Conversely, antibody production is time and resource 
intensive, giving rise to an expensive product where reproducibility 
and consistency are increasingly of concern. Despite an ever 
growing demand, serviced by abundant commercial suppliers, 
significant quality issues concerning both antigen origin and 
antibody characterisation, have as yet to be addressed [13,14]. An 
important point to consider when discussing antibody production 
and supply is immunogenicity. This is a propensity for an antigen 
to stimulate an immune response in a host animal that is in general 
a function of molecular weight. Therefore, whereas conventional 
molecular imprinting favours antigens (templates) with M.W. 
< 1000, antibody production generally requires antigens with 
molecular weights exceeding 6,000 Da [15]. 
With the aim of producing more ‘antibody-like’ materials, 
researchers have invested considerable effort in developing 
water-compatible MIPs to facilitate their direct application in the 
analysis of aqueous samples, including samples of biological 
origin, thus minimising sample pre-treatment and doing away 
with non-polar organic solvent extraction steps from assay 
protocols. This has been achieved by the use of hydrophilic 
building blocks, post-modification of the materials by grafting 
of hydrophilic layers or chemical passivation [16] or, in more 
ambitious cases, by imprinting directly in water using water-
soluble monomers and cross-linkers [17,18]. Such materials 
have been shown to outperform their biological counterparts in 
real sample applications, as they are capable of retaining their 
function in environments that fall outside of normal physiological 
conditions e.g. extremes temperatures and pH values [19].
To date, the imprinting of larger molecules, biological 
macromolecules being the most important member in this 
category, has been hindered by a number of complicating 
factors. The size, complexity, conformational flexibility and 
environmental sensitivity of such molecules, coupled with poor 
target specificity and the lack of recognition by conventional 
imprinted polymers outside organic media, has made this area 
of molecular imprinting particularly challenging and is one 
where true antibody mimicry is quite some way off. However, 
some success has been achieved in the field through careful 
design and optimisation of the imprinted system [18,20,21]. 
Brought to you by | Queens University of Belfast
Authenticated
Download Date | 10/7/15 1:02 PM
J.L. Bowen et al.
38
and pharmaceutical industry rely strongly on the use of organic 
solvents in the majority of their processes, many of which take 
place at elevated temperatures and pH values outside the 
physiological window. An alien environment for any antibody, 
but a place where most MIPs operate best and could provide 
benefits beyond conventional analytical techniques. Lab-scale 
processes, be it a synthetic procedure that requires chiral 
separation or an analytical protocol that requires selective 
isolation of particular compounds, could benefit from the 
flexibility, adaptability and low-cost of MIPs: given a template, 
robust and selective receptors are accessible in 48-72 hours at 
only a fraction of the cost of an antibody. 
Therefore the answer to the commonly asked question “why 
has molecular imprinting had so little commercial impact?” is 
that it has been ‘marketed’ as a solution to a problem that 
did not exist. Clearly, the competitor of the technology is 
not the antibody, but conventional separation science. The 
commercial opportunity perhaps lies in the development of 
MIP solutions to the problems of rapid and cost effective 
analysis of small molecules in non-polar environments. Of 
course existing technologies such as HPLC-MS are well 
entrenched, but opportunities for significant improvement in 
speed, selectivity and/or cost can be envisaged; these could 
be in the form of MIP sensors or highly-automated non-
aqueous binding assays. 
So maybe we need to rephrase the question and ask 
whether we actually need a ‘general alternative to antibodies’. 
It would appear that perhaps we do not and a closer look 
at Figure 2 reveals that the research community has already 
made this decision. Although a steady increase in the number 
of publications comparing MIPs with antibodies has been 
observed since the original paper in 1993, the percentage 
of these publications to the total number of MIP articles has 
the two classes of receptors is not appropriate or helpful. This 
is due to the fact that MIPs are typically highly cross-linked 
organic polymers, insoluble in any solvent, especially water, 
while antibodies are water-soluble biological macromolecules. 
Whilst both of these systems address the same problem, that is 
the need to bind a particular target molecule with good affinity 
and selectivity, they are fundamentally dissimilar in both their 
composition and mode of action. Hence, MIPs can achieve 
affinity and selectivity for their substrate similar to those of an 
antibody but typically in highly organic media where antibodies 
cannot function. Conversely, in physiological conditions where 
antibodies exhibit their full capabilities, most MIPs fail due to 
extreme hydrophobic interactions hindering any specific binding 
event. In the very few recent examples of soluble imprints 
[31,34] the yield of useful polymer is extremely low, typically a 
few milligrams - almost in antibody production quantities, and 
materials are laborious to prepare, thus eliminating the most 
important advantages of the technology: cost-effectiveness, 
simplicity and scalability. Furthermore, however ‘antibody-
like’ soluble imprints are, they are still far from being a ‘general 
alternative’ as favourably oriented substrate functionality is 
required for the imprints to be successful.
Today, the perception of molecular imprinting by the wider 
research community remains mixed whilst its commercial 
impact is modest. It is perhaps worthy to reflect on where 
we might be should researchers have sought to target 
applications for which MIPs were naturally suited rather than 
for those where antibodies are better placed to deliver a 
working solution. The strength of molecular imprinting lies in 
its ability to deliver synthetic receptors capable of targeting low 
molecular weight molecules in non-polar environments. What 
they are not good at is being solubilised, labelled or linked to 
enzyme reporter systems. We should not forget that chemical 
Figure 2.  Cumulative number of articles comparing MIPs to antibodies since the use of the term “antibody mimics” in Vlatakis’ paper (bars) 
and percentage of “antibody mimic” articles to the number of MIP articles published per year (dashed line). Data generated from 
www.mipdatabase.com (accessed on 05/02/2013) [4]
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By no means should this be considered as a failure for the field 
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we have every reason to believe that the full potential of molecular 
imprinting is yet to be revealed and look forward to the exciting 
future of this technology.
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